Becton Dickinson Surges to 20th in Trading Volume with $2.325 Billion Turnover Despite 18.13% Stock Price Decline
1min read On May 1, 2025, Becton Dickinson (BDX) saw a significant surge in trading volume, with a turnover of $2.325 billion, marking a 310.18% increase from the previous day. This substantial rise placed BDX at the 20th position in terms of trading volume for the day. However, the stock price experienced a decline of 18.13%.
Becton Dickinson reported its second-quarter fiscal 2025 financial results, with revenue reaching $5.3 billion, reflecting a 4.5% increase year-over-year. The company's earnings per share (EPS) stood at $1.07 on a GAAP basis and $3.35 on an adjusted basis. The Medical segment and geographic performances continued to drive the company's overall topline growth.
During the earnings call, Becton Dickinson highlighted that its EPS of $3.35 exceeded the forecast of $3.28 by 2.1%. However, the reported revenue of $5.27 billion fell short of expectations by approximately 1.5%. The company's profits for the quarter were $308 million, equating to $1.07 per share on sales of $5.27 billion. Despite a 4.5% increase in sales, the company recorded a 42.6% decline in bottom-line performance.
Becton Dickinson adjusted its guidance for the fiscal year 2025 to account for the potential impact of tariffs announced by the Trump Administration. The company now expects revenues to range between $21.8 billion and $21.9 billion, reflecting updated organic revenue growth guidance of 3% to 3.5%. Before the tariff impact, the company projects adjusted diluted EPS to be in line with its previous guidance of $14.30 to $14.60. The estimated tariff impact for the fiscal year is approximately 25¢, resulting in a projected EPS range of $14.06 to $14.34.
Tom Polen, BD's chair, president, and CEO, commented on the company's performance, stating that despite a challenging operating environment, the second-quarter results demonstrated the strength of BD's business model. The company's BD Excellence operating system continues to drive margin expansion and investment in commercial organization and innovation. Polen expressed confidence in BD's ability to accelerate growth as markets recover and navigate the current macro environment, leveraging its scale as the largest U.S. manufacturer of medical devices for long-term value creation.
